ES2169025T3 - Compuestos, vectores y procedimiento para expresar fosfolipasa a2 citosolica humana. - Google Patents

Compuestos, vectores y procedimiento para expresar fosfolipasa a2 citosolica humana.

Info

Publication number
ES2169025T3
ES2169025T3 ES92303209T ES92303209T ES2169025T3 ES 2169025 T3 ES2169025 T3 ES 2169025T3 ES 92303209 T ES92303209 T ES 92303209T ES 92303209 T ES92303209 T ES 92303209T ES 2169025 T3 ES2169025 T3 ES 2169025T3
Authority
ES
Spain
Prior art keywords
compounds
vectors
human
citosolica
procedure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92303209T
Other languages
English (en)
Inventor
Xue-Chiou Chen Chiou
Jo Ann Hoskins
Ruth Maria Kramer
John David Sharp
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Application granted granted Critical
Publication of ES2169025T3 publication Critical patent/ES2169025T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

LA INVENCION SE REFIERE A COMPUESTOS DE ADN RECOMBINANTE, VECTORES Y METODOS UTILES PARA EXPRESAR UNA ENZIMA DE FOSFOLIPASA A2 CITOSOLICA (CPLA2), HUMANA, EXCEPCIONALMENTE EXTRAÑA. LA INVENCION SE REFIERE TAMBIEN A UN METODO PARA SEPARAR COMPUESTOS PARA IDENTIFICAR LOS INHIBIDORES DE LA CPLA2 QUE SE PIENSAN TOMAN PARTE EN MUCHOS PROCESOS DE ENFERMEDADES.
ES92303209T 1991-04-17 1992-04-10 Compuestos, vectores y procedimiento para expresar fosfolipasa a2 citosolica humana. Expired - Lifetime ES2169025T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US68655891A 1991-04-17 1991-04-17

Publications (1)

Publication Number Publication Date
ES2169025T3 true ES2169025T3 (es) 2002-07-01

Family

ID=24756805

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92303209T Expired - Lifetime ES2169025T3 (es) 1991-04-17 1992-04-10 Compuestos, vectores y procedimiento para expresar fosfolipasa a2 citosolica humana.

Country Status (6)

Country Link
US (1) US5328842A (es)
EP (1) EP0509719B1 (es)
JP (1) JPH0829103B2 (es)
CA (1) CA2066111A1 (es)
ES (1) ES2169025T3 (es)
IL (1) IL101507A0 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL99227A (en) * 1990-08-24 1996-10-16 Lilly Co Eli Phosphorus lipase A2 cytosolic human
DE69423436T2 (de) 1993-06-25 2000-09-07 Smithkline Beecham Plc An lipoprotein gebundene phospholipase a2, inhibitoren davon und deren verwendung für diagnose und therapie
US5453443A (en) * 1994-07-20 1995-09-26 Merck Frosst Canada, Inc. Bis(aryloxy)alkanes as inhibitors of phospholipase A2 enzymes
US5466595A (en) * 1994-07-27 1995-11-14 Genetics Institute, Inc. Calcium independent cytosolic phospholipase A2/B enzymes
US6274140B1 (en) 1994-07-27 2001-08-14 Genetics Institute, Inc. Calcium independent cytosolic phospholipase A2/B enzymes
US5707821A (en) * 1995-06-07 1998-01-13 Athena Neurosciences, Inc. Identification of phospholipase A2 inhibitors in Aβ peptide-mediated neurodegenerative disease
US5866318A (en) * 1995-06-07 1999-02-02 Athena Neurosciences, Inc. Inhibition of phospholipase A2 to reduce neuronal cell death
WO1996040982A1 (en) * 1995-06-07 1996-12-19 Athena Neurosciences, Inc. Therapeutic inhibition of phospholipase a2 in neurodegenerative disease
US5994398A (en) * 1996-12-11 1999-11-30 Elan Pharmaceuticals, Inc. Arylsulfonamides as phospholipase A2 inhibitors
US6287838B1 (en) 1997-01-24 2001-09-11 Genetics Institute, Inc. Cytosolic phospholipase A2-Beta enzymes
US6103510A (en) * 1997-03-21 2000-08-15 Eli Lilly And Company Human phospholipase A2 and related nucleic acid compounds
US6801860B1 (en) * 1999-02-15 2004-10-05 Genetics Institute, Llc Crystal structure of cPLA2 and methods of identifying agonists and antagonists using same
CN1122106C (zh) * 2000-09-18 2003-09-24 中山大学 一种平颏海蛇磷脂酶a2以及编码它的基因
US20020165119A1 (en) * 2001-01-31 2002-11-07 Alan Leff Method of treating inflammatory conditions by inhibiting cytosolic phospholipase A2
EP1358329A2 (en) * 2001-02-06 2003-11-05 Incyte Genomics, Inc. Lipid-associated molecules
US20040001106A1 (en) * 2002-06-26 2004-01-01 John Deutscher System and process for creating an interactive presentation employing multi-media components
JP4566750B2 (ja) * 2002-12-02 2010-10-20 カウンシル オブ サイエンティフィック アンド インダストリアル リサーチ パラブロモフェナシル・ブロマイド（ｐｂｐｂ）を用いた喘息の予防および／または治療法
US20070264246A1 (en) * 2005-10-05 2007-11-15 Gross Richard W ENHANCED MEDICAL TREATMENTS RESULTING FROM CHEMICAL IDENTIFICATION OF CALCIUM INFLUX FACTOR, IDENTITY WITH THE FACTOR ACTIVATING PHOSPHOLIPOLYSIS AND PRECIPITATING SUDDEN DEATH DURING MYOCARDIAL INFARCTION, AND DETERMINATION OF SIMILAR ACTIVATING MECHANISMS IN MULTIPLE CELL TYPES THROUGH DISINHIBITION OF CALCIUM-INDEPENDENT PHOSPHOLIPASE A2beta

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2872256B2 (ja) * 1987-08-27 1999-03-17 イーライ リリー アンド カンパニー 滑膜ホスホリパーゼ
AU3548289A (en) * 1988-04-15 1989-11-03 Biogen, Inc. Processes for purifying phospholipase a2 and producing phospholipase a2-like polypeptides
JPH0265781A (ja) * 1988-08-29 1990-03-06 Shionogi & Co Ltd ヒト膵蔵ホスホリパーゼａ↓２の製造法

Also Published As

Publication number Publication date
US5328842A (en) 1994-07-12
EP0509719B1 (en) 2001-12-19
CA2066111A1 (en) 1992-10-18
IL101507A0 (en) 1992-12-30
JPH0829103B2 (ja) 1996-03-27
EP0509719A1 (en) 1992-10-21
JPH05103677A (ja) 1993-04-27

Similar Documents

Publication Publication Date Title
ES2169025T3 (es) Compuestos, vectores y procedimiento para expresar fosfolipasa a2 citosolica humana.
ES2145580T3 (es) Metodos y composiciones para analizar moleculas de acido nucleico que emplean tecnicas basadas en el tamaño.
CY1105364T1 (el) Μεθοδοι και συνθεσεις διαμορφωσης ανοσοποιησης
EA199800857A1 (ru) Композиция для снятия боли и способ снятия боли
DE69232682D1 (de) Verfahren zur selektiven vermehrung von cd34 positiven zellen
IL130036A0 (en) Survivin a protein that inhibits cellular apoptosis and its modulation
DZ2310A1 (fr) Procédé sismique à source vibratrice haute fidélité.
EA199700087A1 (ru) Способ ингибирования катепсина к
DE3763653D1 (de) Trennungsverfahren fuer kohlenwasserstoffgase.
GB2330655A (en) Method and system for performing a binding assay
NO994998D0 (no) Fusjonsproteiner
MX9201113A (es) Metodo para identificar o tamizar agonistas o antagonistas de la amilina.
KR950700779A (ko) 단백질의 정제방법(Protein purification)
ES2162277T3 (es) Sustratos e inhibidores de enzimas proteoliticos.
BR9912545A (pt) ácidos nucleicos codificando um receptorcopulado a proteìna g envolvido em transduçãosensorial
MX9203519A (es) Metodo de recombinacion para la produccion de inhibidores de proteasa de serina y secuencias de adn utiles para los mismos.
NO885670L (no) Fortilsetning og for som inneholder denne tilsetning.
NO885013D0 (no) FremgangsmŸte for fremstilling av bionedbrytbare mikrokapsler av vannopplelige peptider og proteiner, samt mikroka psler oppnŸdd ved fremgangsmŸten.
DE3668884D1 (de) Verfahren zur optischen trennung von dl-cystein und (r,s)-1-(1-naphthyl)ethylamin.
ATE316577T1 (de) Das goodpasture-antigen bindende protein
DK0815231T3 (da) Anvendelse af neuronalt apoptosisinhibitorprotein (NAIP)
ES2161807T3 (es) Procedimiento para la determinacion cuantitativa de proteinas glucosiladas.
DE3784039T2 (de) Verfahren zur acrylamid-aufspaltung.
ES2236703T3 (es) Uso de metodos para identificar oligopeptidos de señal hidrofilos.
DE69814806T2 (de) Hochdruckverfahren zur Rückgewinnung von Schwefel

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 509719

Country of ref document: ES